In the process of acquiring 100% stake in Netherlands-based specialty pharmaceutical company OctoPlus NV, Dr Reddy’s Laboratories has, so far, acquired 79.4% stake of Octoplus. Of the aforementioned stake, the company has bought 15.9% shares (83,59,858 shares) through open market and 63.5% shares (3,34,48,839 shares) were committed by certain members of the OctoPlus Board and other shareholders though irrevocable undertaking.
The entire acquisition is expected to be completed by the end of the current financial year. As per the agreement, Dr Reddy’s made an open offer to purchase all outstanding shares of OctoPlus at an offer price of 0.52 euro in cash for each share.
Dr Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: